Actively Recruiting
GENOSS Coronary Stent Clinical Trial
Led by Samsung Medical Center · Updated on 2022-07-06
850
Participants Needed
1
Research Sites
270 weeks
Total Duration
On this page
Sponsors
S
Samsung Medical Center
Lead Sponsor
G
Genoss Company Limited, Suwon, Korea
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study aims to evaluate the efficacy and safety of abluminal biodegradable polymer ultrathin sirolimus-eluting stent (Genoss stent) as compared with a durable-polymer everolimus-eluting stent (Xience stent) in patients with coronary artery disease.
CONDITIONS
Official Title
GENOSS Coronary Stent Clinical Trial
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Subject must be at least 19 years of age
- Subject who is able to understand risks, benefits and treatment alternatives and sign informed consent voluntarily
- Patients with stable coronary artery disease or acute coronary syndrome and at least one lesion with greater than 50% diameter stenosis suitable for stent implantation
You will not qualify if you...
- Pregnant women
- Patients unable to provide consent
- Patients with known intolerance to aspirin, clopidogrel, ticagrelor, prasugrel, heparin or components of drug-eluting stents (sirolimus or everolimus)
- Patients who have non-cardiac co-morbid conditions with life expectancy less than 1 year or that may result in protocol non-compliance (per site investigator's medical judgment)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Cardiac and Vascular Center; Samsung Medical Center
Seoul, South Korea, 135-710
Actively Recruiting
Research Team
H
Hyeon-Cheol Gwon, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here